UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 147

Sortiert nach

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

The lancet oncology, 2015-01, Vol.16 (1), p.67-75

2015

Volltextzugriff (PDF)

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

The lancet oncology, 2010-12, Vol.11 (12), p.1135-1141

2010

Volltextzugriff (PDF)

Markers for the identification of late breast cancer recurrence

Breast cancer research : BCR, 2015-01, Vol.17 (1), p.10-10, Article 10

2015

Volltextzugriff (PDF)

Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer

JNCI : Journal of the National Cancer Institute, 2018-02, Vol.110 (2), p.166-175

2018

Volltextzugriff (PDF)

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer

Breast cancer research and treatment, 2021-02, Vol.186 (1), p.115-123

2021

Volltextzugriff (PDF)

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Journal of clinical oncology, 2013-08, Vol.31 (22), p.2783-2790

2013

Volltextzugriff (PDF)

Overlap microtubules link sister k-fibres and balance the forces on bi-oriented kinetochores

Nature communications, 2016-01, Vol.7 (1), p.10298-10298, Article 10298

2016

Volltextzugriff (PDF)

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

The Lancet (British edition), 2014-03, Vol.383 (9922), p.1041-1048

2014

Volltextzugriff (PDF)

Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial

The lancet oncology, 2008-12, Vol.9 (12), p.1143-1148

2008

Volltextzugriff (PDF)

Factors Predicting Late Recurrence for Estrogen Receptor―Positive Breast Cancer

JNCI : Journal of the National Cancer Institute, 2013-10, Vol.105 (19), p.1504-1511

2013

Volltextzugriff (PDF)

Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score

Journal of clinical oncology, 2015-03, Vol.33 (8), p.916-922

2015

Volltextzugriff (PDF)

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

The lancet oncology, 2013-10, Vol.14 (11), p.1067-1076

2013

Volltextzugriff (PDF)

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial

British journal of cancer, 2021-04, Vol.124 (8), p.1373-1378

2021

Volltextzugriff (PDF)

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

The Lancet (British edition), 2013-05, Vol.381 (9880), p.1827-1834

2013

Volltextzugriff (PDF)

Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial

Journal of clinical oncology, 2010-07, Vol.28 (21), p.3411-3415

2010

Volltextzugriff (PDF)

CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

JNCI : Journal of the National Cancer Institute, 2012-03, Vol.104 (6), p.452-460

2012

Volltextzugriff (PDF)

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

The Lancet (British edition), 2016-02, Vol.387 (10021), p.866-873

2016

Volltextzugriff (PDF)

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

BMC medical genomics, 2015-08, Vol.8 (1), p.54-54, Article 54

2015

Volltextzugriff (PDF)

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

The lancet oncology, 2011-01, Vol.12 (1), p.21-29

2011

Volltextzugriff (PDF)

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

The lancet oncology, 2008-09, Vol.9 (9), p.866-872

2008

Volltextzugriff (PDF)

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies

Breast cancer research and treatment, 2021-07, Vol.188 (1), p.215-223

2021

Volltextzugriff (PDF)

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials

Journal of clinical oncology, 2017-03, Vol.35 (7), p.743-750

2017

Volltextzugriff (PDF)

Aromatase Inhibitor–Induced Carpal Tunnel Syndrome: Results From the ATAC Trial

Journal of clinical oncology, 2009-10, Vol.27 (30), p.4961-4965

2009

Volltextzugriff (PDF)

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial

Breast (Edinburgh), 2020-12, Vol.54, p.216-221

2020

Volltextzugriff (PDF)

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial

The lancet oncology, 2014-12, Vol.15 (13), p.1460-1468

2014

Volltextzugriff (PDF)

1 – 25 von 147

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(140)

Publikationsform

Artikel
(143)
Berichte
(2)
Reviews
(1)
Webseiten
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(83)
Humans
(66)
Female
(57)
Oncology
(54)
Middle Aged
(41)
Breast Cancer
(39)
Breast Neoplasms - Drug Therapy
(33)
Aged
(30)
Tamoxifen - Therapeutic Use
(27)
Prognosis
(24)
Antineoplastic Agents, Hormonal - Therapeutic Use
(23)
Anastrozole
(21)
Breast Neoplasms - Genetics
(21)
Breast Neoplasms - Pathology
(20)
Risk Factors
(20)
Breast Neoplasms - Prevention & Control
(18)
Tumors
(18)
Adult
(17)
Treatment Outcome
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Markers for the identification of late breast cancer recurrence

Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Overlap microtubules link sister k-fibres and balance the forces on bi-oriented kinetochores

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial

Factors Predicting Late Recurrence for Estrogen Receptor―Positive Breast Cancer

Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial

CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials

Aromatase Inhibitor–Induced Carpal Tunnel Syndrome: Results From the ATAC Trial

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial

Suchergebnisse filtern